AnalystsJames QuigleyJames Quigley's Stock Forecasts
AnalystsJames Quigley
Analyst Ranking
Top 36%
#1788 out of 4995 analysts
Average Return
+65.31%
Win Rate
75%3 out of 4
Risk vs Reward
Poor
Good
James Quigley's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Morphosys AgMOR | +191.69% | $6.50 | $18.96 | 2023-10-12 - 2024-08-02 | Strong Buy |
Ablynx NvABLX | +129.87% | $23.00 | $52.87 | 2017-11-19 - 2018-06-12 | Strong Buy |
Kymera Therapeutics IncKYMR | +1.19% | $43.58 | $44.10 | 2025-06-02 - 2025-08-22 | Strong Buy |
James Quigley Analyst Color
Get additional color on James Quigley's coverage of popular stocks
James Quigley's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Kymera Therapeutics IncKYMR | 6 | Strong Buy | $79.00 | +79.14% | Upgrades | 3 months ago |
SanofiSNY | 1 | Hold | $65.00 | +26.58% | Initiates Coverage On | 5 months ago |
Novartis AgNVS | 1 | Hold | $121.00 | -4.71% | Downgrades | a year ago |
Grifols SaGRFS | 1 | Hold | $10.50 | N/A | Maintains | 2 years ago |
Morphosys AgMOR | 3 | Strong Buy | $9.20 | N/A | Upgrades | 2 years ago |
Galapagos NvGLPG | 10 | Hold | $40.00 | N/A | Maintains | 2 years ago |
EVO | 1 | Strong Buy | $16.00 | N/A | Upgrades | 2 years ago |
Evotec SeEVO | 1 | Strong Sell | $16.00 | N/A | Downgrades | 3 years ago |
Ablynx NvABLX | 1 | Strong Buy | $25.00 | N/A | Initiates Coverage On | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.